Progress of diagnosis and treatment of light chain amyloidosis
10.3760/cma.j.issn.1009-9921.2019.01.016
- VernacularTitle:轻链型淀粉样变性的诊断及治疗进展
- Author:
Zeyu LIN
1
;
Wenming CHEN
Author Information
1. 首都医科大学附属北京朝阳医院血液科 100020
- Keywords:
Amyloidosis;
Diagnosis;
Treatment
- From:
Journal of Leukemia & Lymphoma
2019;28(1):57-60
- CountryChina
- Language:Chinese
-
Abstract:
Systemic amyloidosis is caused by misfolding of heavy or light chain in immune globulin and extracellular deposition of proteins as amyloid fibrils. The most common form is light chain amyloidosis, which results in dysfunction of vital organs. Specific biomarkers and amyloid imaging can prompt organ dysfunction at early diagnosis and prevent the organ failure at end stage. Combination therapy is the direction of light chain amyloidosis therapy in the future. The studies on the target therapy concerning clone light chain and amyloid deposition, and new drugs that can control light chain gathering and hydrolysis are under exploration. This paper reviews the treatment progress of light chain amyloidosis.
